Search
UPTRAVI 1000 µG, Comprimé pélliculé
Details
| --- | Description |
|---|---|
| Pack | Boite de 60 |
| Strength (Dosage) | 1000 µG |
| Laboratory | MAPHAR |
| Ingredients | Sélexipag |
| Therapeutic class | Antihypertenseur pulmonaire, agoniste sélectif du récepteur IP |
| ATC code | B01AC27 |
| PPH | $2,900.10 |
| PPV | $2,957.30 |
| Refundable | No |
| Refund base | $0.00 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Not specified |
| Uses | Traitement de l'hypertension artérielle pulmonaire (HTAP) chez les patients atteints d'une limitation fonctionnelle avancée (classe fonctionnelle III/IV de la NYHA) pour retarder la progression de la maladie. |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications with one or more of the ingredients above
Medications under one or more of the therapeutic classes above
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem